Microarray Patch (General)
MAP, Microneedle Patch
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Intradermal
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): PATH, Micron, Queen's University Belfast, ViiV Healthcare, Population Council, LTS Lohmann Therapie-Systeme AG, FHI 360, Georgia Tech, University of Michigan, Istanbul University, Indian Institute of Technology Bombay, Wuhan University, Tufts University
Details
- API: Not Yet Determined
- Target: Not Yet Determined
-
Mechanism of Action:
- Not Yet Determined
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Potential MPT
- Promising Attributes: Microarray patches are discrete, associated with minimal pain or irritation, and are intended to have a longer-acting duration, bridging short-acting methods like OCPs and long-acting methods like LARCs.
Product Status
Active or Recent Pre-Clinical Development by Multiple Entities
History
A number of micro-array patch concepts for contraception have advanced in academic, industry, and non-profit development contexts, and have been the subject of sociobehavioral studies indicating user interest. These concepts have not advanced beyond prototype development, limited animal studies, and placebo trials. Development is ongoing.
Publications
doi: 10.3390/pharmaceutics16070946
doi: 10.3389/frph.2024.1351692
doi: 10.1371/journal.pone.0290568
doi: 10.3389/frph.2023.1125159
doi: 10.1016/j.jconrel.2022.04.051
doi: 10.3390/molecules27072349
doi: 10.1016/j.ijpharm.2021.121332
doi: 10.1016/j.jconrel.2021.08.012
doi: 10.1186/s12978-021-01113-y
doi: 10.1021/acsabm.0c00671
doi: 10.1126/sciadv.aaw8145
doi: 10.1371/journal.pone.0216797
doi: 10.1038/s41551-018-0337-4